Cart
sales@molnova.com
PF07104091
CAS No. 2460249-19-6
PF07104091( PF-07104091 )
Catalog No. M28851 CAS No. 2460249-19-6
PF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 491 | Get Quote |
|
| 5MG | 780 | Get Quote |
|
| 10MG | 1143 | Get Quote |
|
| 25MG | 1701 | Get Quote |
|
| 50MG | 2295 | Get Quote |
|
| 100MG | 3087 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePF07104091
-
NoteResearch use only, not for human use.
-
Brief DescriptionPF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
-
DescriptionPF-07104091 inhibits CDK2, which may lead to cell cycle arrest, induce apoptosis and inhibit tumor cell proliferation.
-
In Vitro——
-
In Vivo——
-
SynonymsPF-07104091
-
PathwayAngiogenesis
-
TargetCDK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2460249-19-6
-
Formula Weight404.46
-
Molecular FormulaC19H28N6O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C(=O)C1=CC(COC)=NN1C)C2=CC(=NN2)[C@@H]3C[C@H](OC(NC(C)C)=O)CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yamaguchi T, et al. Determination of 7-chloro-3-(4-methyl-1-piperazinyl)-4h-1,2,4-benzothiadiazine-1,1-dioxide (DU-717) in plasma using electron-capture gas chromatography. J Chromatogr. 1978 Oct 11;160(1):181-90.
molnova catalog
related products
-
HQ461
HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death.
-
BI-1347
BI-1347 is a potent, selective inhibitor of CDK8/cyclinC with IC50 of 1 nM。
-
CDK9-IN-2
CDK9-IN-2 is a potent and selective CDK9 inhibitor with IC50 of <8 nM, example 4 in patent WO2011026917A1.
